[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperaldosteronism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperaldosteronism":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,78,108,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100535017","phase-2-evaluating-the-functional-status-of-the-adrenal-glands-with-68gaga-pentixafor-in-hyperaldosteronism-and-hypercortisolism-100535017",false,"NCT06246357","Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism","Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism","* INCLUSION CRITERIA:\n* Must have any of the following:\n\n  * one or more adrenal masses on CT and\u002For MRI and biochemical evidence of excess aldosterone\n\nOR\n\n--ACTH-independent hypercortisolism, with or without adrenal masses on CT and\u002For MRI\n\nOR\n\n* history of ACTH-dependent hypercortisolism (with or without adrenal enlargement)\n* Co-enrollment in 19-DK-0066, 09-C-0242, 18-CH-0031 or a similar NIH trial.\n* Age \\>=18 years.\n* ECOG performance status \\\u003C= 2.\n* Women of child-bearing potential (WOCBP) and men must agree to use an effective contraception (barrier, hormonal, intrauterine device \\[IUD\\], surgical sterilization, abstinence) for two weeks prior to \\[68Ga\\]Ga-PentixaFor scan and for one week after the \\[68Ga\\]Ga-PentixaFor scan.\n\n  * Breastfeeding should be discontinued for one week after the \\[68Ga\\]Ga-PentixaFor scan.\n  * Men must agree not to donate sperm for one week after the \\[68Ga\\]Ga-PentixaFor scan.\n* Participants must be able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening.\n* Uncontrolled intercurrent illness or social situations based on the review of medical history that would limit compliance with study requirements.\n* Contraindications to having an MRI and CT.","ALL","18 Years","120 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nThe adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works. Tumors on or outside the adrenal glands are called functional if they release hormones; they are called nonfunctional if they do not. Doctors who treat adrenal tumors need to know which type a person has. Researchers want to find better ways to learn whether an adrenal tumor is functional.\n\nObjective:\n\nTo see if a new radioactive tracer (\\[68Ga\\]Ga-PentixaFor) can make it easier to identify functional adrenal tumors with positron emission tomography (PET) scans.\n\nEligibility:\n\nPeople aged 18 years and older with 1 or more adrenal tumors. They must have increased levels of the hormones aldosterone or cortisol. They must also be enrolled in at least 1 other related NIH study (protocols 19-DK-0066, 18-CH-0031, or 09-C-0242).\n\nDesign:\n\nParticipants will be screened. They may have imaging scans. Their ability to perform normal activities will be reviewed.\n\nParticipants will have one PET scan with the study tracer.\n\nThe tracer will be given through a tube attached to a needle inserted into a vein. Participants will receive the tracer 1 hour before the scan. They will lie still on a bed while a machine captures images of the inside of their body. The scan will take 45 to 90 minutes.\n\nParticipants heart rate, blood pressure, and rate of breathing will be checked before, during, and after the scan.\n\nParticipants will have a follow-up visit 3 days after their scan. This visit can be by phone, email, or in person.",[27,28,29],"Hyperaldosteronism","Hypercortisolism","Cushing s Syndrome",[31,32],"Adenomas","PET Imaging","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":37},"2024-09-23",{"date":41,"type":21},"2028-04-01",{"name":43,"class":44},"National Cancer Institute (NCI)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100618177","superselective-adrenal-arterial-embolization-versus-oral-spironolactone-for-treatment-of-idiopathic-hyperaldosteronism-100618177","NCT07328230","Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism","A Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral Spironolactone","Inclusion Criteria:\n\n1. Aged from 15 to 60 with no limits in sex;\n2. Patients are diagnosed with primary aldosteronism according to the criteria of the 2016 Endocrine Society guidelines;\n3. Sub-typing diagnosis confirmed idiopathic hyperaldosteronism;\n4. Patients or their legal representatives have to sign written informed consent approved by the ethics committee.\n\nExclusion Criteria:\n\n1. Unilateral adrenal hyperplasia;\n2. Renal insufficiency with an estimated glomerular filtration rate (based on the modification of diet in renal disease criteria) \\\u003C45 ml\u002Fmin\u002F1.73 m², and\u002For serum creatinine \\>176 μmol\u002FL；\n3. Hemorrhagic or ischemic stroke, endovascular stent implantation and myocardial infarction within the previous 3 months;\n4. Severe contrast agent allergy;\n5. Women who are pregnant or planning to become pregnant;\n6. Patients with other serious organic diseases cannot tolerate SAAE treatment;\n7. Other forms of secondary hypertension.","15 Years","60 Years",{"count":56,"type":21},172,[58],"NA","Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.",[61,27],"Idiopathic Hyperaldosteronism",[63,64,27,65,66],"Superselective adrenal arterial embolization","Spironolactone","Hypertension","Mineralocorticoid receptor antagonists(","2025-12-26",{"date":69,"type":37},"2026-01-09",{"date":71,"type":37},"2022-08-01",{"date":73,"type":21},"2025-12-31",{"name":75,"class":76},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",3,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100612338","china-adrenal-venous-sampling-investigation-100612338","NCT07252284","CHina Adrenal Venous saMPling InvestigatiON","China Adrenal Venous Sampling Investigation: A National Multicenter Study","CHAMPION","Inclusion Criteria:\n\n1. Patients with confirmed primary aldosteronism;\n2. Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism.\n\nExclusion Criteria:\n\n1. Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；\n2. An estimated glomerular filtration rate \\\u003C45 ml\u002Fmin\u002F1.73 m2, or serum creatinine \\>176 μmol\u002FL；\n3. Patients who refuse adrenalectomy;\n4. Suspected of having an adrenocortical carcinoma;\n5. Allergy to contrast agent;\n6. Pregnant, nursing, or planning to become pregnant",{"count":87,"type":21},5000,"5 Years","OBSERVATIONAL","Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.",[27,92,93],"Adrenal Venous Sampling","Adrenalectomy",[95,27,96,97,98],"Adrenal venous sampling","Antecubital approach","Femoral approach","Main adverse cardiovascular events","2025-11-19",{"date":101,"type":37},"2025-11-26",{"date":103,"type":37},"2025-05-01",{"date":105,"type":21},"2029-08-31",{"name":75,"class":76},76,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":16,"minAge":17,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100272914","primary-aldosteronism-in-western-norway-100272914","NCT02832388","Primary Aldosteronism in Western Norway","Primary Aldosteronism: a Study of Diagnostic Approach and Treatment Outcome in Western Norway","Inclusion Criteria:\n\n* Verified diagnosis or strong suspicion of primary aldosteronism\n* Age 18-85\n\nExclusion Criteria:\n\n* Active cancer disease at time of inclusion\n\nExclusion criteria for subgroup of primary aldosteronism-patients and healthy controls who perform cardiac MRI:\n\n* Asthma\u002Fchronic obstructive pulmonary disease ,\n* Use of dipyridamole\n* Claustrophobia",true,"85 Years",{"count":118,"type":21},300,"In this study the investigators aim to identify and include consecutively patients with primary aldosteronism (PA) diagnosed in the Western and Mid-parts of Norway, to describe the characteristics of these patients, to explore the cardiac effects of PA before and after specific treatment, and to identify long-term outcomes after treatment. One subgroup of the PA patients perform echocardiography to assess left ventricular systolic myocardial function before and after treatment. One subgroup of PA patients perform cardiac MRI to assess myocardial mass, myocardial fibrosis and myocardial function in rest and during stress, before and after treatment. For the cardiac MRI substudy, the PA patients are compared with a group of healthy controls, also included in the study.\n\nFrom 2022 onwards, PA patients diagnosed or subtyped with adrenal vein sampling at Oslo University Hospital will additionally be included in the study, thereby providing a national registration of PA patients.",[27],"2024-11-07",{"date":123,"type":37},"2024-11-08",{"date":125,"type":4},"2013-06",{"date":127,"type":21},"2030-12",{"name":129,"class":76},"Haukeland University Hospital",2,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":142,"studyType":89,"phases":4,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100530857","china-national-study-of-adrenal-venous-sampling-100530857","NCT06192238","China National Study of Adrenal Venous Sampling","A National Multicenter Study of Adrenal Venous Sampling for the Subtype Diagnosis of Primary Aldosteronism in China","CNAVS","Inclusion Criteria:\n\n1. Aged from 18 to 65 with no limits in sex;\n2. Patients with confirmed primary aldosteronism;\n3. Patients or their legal representatives sign written informed consent approved by the ethics committee；\n\nExclusion Criteria:\n\n1. Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；\n2. An estimated glomerular filtration rate \\\u003C45 ml\u002Fmin\u002F1.73 m2, or serum creatinine \\>176 μmol\u002FL；\n3. Patients who refuse adrenalectomy;\n4. Suspected of having an adrenocortical carcinoma;\n5. Allergy to contrast agent;\n6. Pregnant, nursing, or planning to become pregnant","65 Years",{"count":141,"type":21},1500,"3 Years","This multicenter study intends to combine retrospective analysis and prospective registry to evaluate the success rate and safety of adrenal venous sampling (AVS) via antecubital and femoral approach for patients with primary aldosteronism. The consistency of AVS with pathological results and clinical outcomes, the factors affecting the success of AVS, and the optimal population for AVS will be aslo analyzed in this study.",[27],[95,27,96,97,146],"Pathological results","NOT_YET_RECRUITING","2024-01-05",{"date":150,"type":37},"2024-01-09",{"date":152,"type":21},"2024-01-01",{"date":154,"type":21},"2026-12-30",{"name":75,"class":76},48]